RSS

Savara Pharmaceuticals

US group Savara Pharmaceuticals has secured $10 million in financial backing to develop AeroVanc, the trade name of the first inhaled antibiotic designed to address the growing number of MRSA lung infections in cystic fibrosis patients. more

16 Oct 2014 14:59